Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > 13 G filing

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Nov 14, 2022 8:25pm

107 Views

Post# 35098471

RE:RE:RE:RE:RE:RE:RE:RE:RE:13 G filing

Your math is wrong

PWIB123 wrote: If you subtract out the 1,550,000 shares represented by warrants, Soleus' ownership in various entities now owns a total 8,125,909 shares, plus the 1,550,000 warrants. As of 6/30, they reported 7,822,412 under Soleus Capital Management. The Master Fund owns the warrants, so they definitely increased shares over the last 5 months.

SPCEO1 wrote: While it is always hard to understand Soleus' filings because of how they treat the warrants, it appears they have added to their postion and that was the reason for their filing. It is separate from the 7.5 million share block trade which may be related to intercompany accoutning moves at Morgan Stanley? If so, that indicates they may ahve bought more shares too since they did not own 7.5 million shares as of 6/30.

qwerty22 wrote:
"The shares of common stock reported in this row are held by Soleus Capital Master Fund, L.P. (“Master Fund”), and include a presently exercisable warrant to purchase up to 1,550,000 shares of common stock at an exercise price of $3.14 per share (the “Warrant”). Soleus Capital, LLC is the sole general partner of Master Fund and thus holds voting and dispositive power over the shares held by Master Fund. "

So for people that don't understand these types of transactions, like me, why would Soleus do this?

palinc2000 wrote:

https://www.theratech.com/static-files/446de95b-5b8e-4464-9058-dd6bbd822fc7

SPCEO1 wrote: I cannot find that filing - where did you see it? Is it from today?

palinc2000 wrote:

My understsnfing is that the Filing is simply to account for the transfer of the shsres ftom Soleus to a General Partner controlled by Soleus

palinc2000 wrote: [The 9.5 mil'ion includes 1555000 warrabts

quote=palinc2000]

Seems like Soleus hold 9.5 million shares representing 10.1 %

palinc2000 wrote: Soleus